|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.53 USD | +0.47% |
|
-4.23% | -28.16% |
| 28/06 | Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating | MT |
| 28/06 | Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi | MT |
June 28 (Reuters) - The U.S. Food and Drug Administration has declined to approve Rocket Pharmaceuticals' gene therapy to treat a rare and severe pediatric disorder that causes the immune system to malfunction, the company said on Friday.
(Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.16% | 1.95B | |
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
ROCKET PHARMACEUTICALS, INC. 
